Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1 / Phase 2interventionalRules rewrite

Phase 1 / Phase 2: testing SHR-1701 for Metastatic Pancreatic Cancer

The goal of this clinical trial is to measure the safety and how well it works of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma.

Official registry: https://clinicaltrials.gov/study/NCT07802184 · West China Hospital · enrollment listed as 45

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are SHR-1701, Apatinib, or gemcitabine. The registry lists allocation as na. The goal of this clinical trial is to measure the safety and how well it works of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma.

They plan to enroll about 45 people at Chengdu. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial

Interventions: SHR-1701, Apatinib, gemcitabine, Nab-paclitaxel

Primary outcome (registry wording): Recommended Phase II Dose (RP2D)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 75 Years

Public study contact (from the registry)

Dan Cao

+8618980605963

caodan@scu.edu.cn

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingPhase 2Bethesda, Maryland
Phase 2: testing Pembrolizumab (Keytruda) for Metastatic Colorectal Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.

NCT01174121 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT07802184 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07802184?

Phase 1 / Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07802184?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary